194 related articles for article (PubMed ID: 18305034)
1. Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.
Mirsaliotis A; Lamb D; Brighty DW
J Virol; 2008 May; 82(10):4965-73. PubMed ID: 18305034
[TBL] [Abstract][Full Text] [Related]
2. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope.
Lamb D; Schüttelkopf AW; van Aalten DM; Brighty DW
Retrovirology; 2008 Aug; 5():70. PubMed ID: 18680566
[TBL] [Abstract][Full Text] [Related]
3. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.
Piñón JD; Kelly SM; Price NC; Flanagan JU; Brighty DW
J Virol; 2003 Mar; 77(5):3281-90. PubMed ID: 12584351
[TBL] [Abstract][Full Text] [Related]
4. Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.
Lamb D; Mirsaliotis A; Kelly SM; Brighty DW
J Biol Chem; 2009 Mar; 284(10):6575-84. PubMed ID: 19114713
[TBL] [Abstract][Full Text] [Related]
5. An antibody that blocks human T-cell leukemia virus type 1 six-helix-bundle formation in vitro identified by a novel assay for inhibitors of envelope function.
Mirsaliotis A; Nurkiyanova K; Lamb D; Kuo CS; Brighty DW
J Gen Virol; 2007 Feb; 88(Pt 2):660-669. PubMed ID: 17251585
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.
Porotto M; Carta P; Deng Y; Kellogg GE; Whitt M; Lu M; Mungall BA; Moscona A
J Virol; 2007 Oct; 81(19):10567-74. PubMed ID: 17652384
[TBL] [Abstract][Full Text] [Related]
7. Resistance to neutralization by antibodies targeting the coiled coil of fusion-active envelope is a common feature of retroviruses.
Mirsaliotis A; Nurkiyanova K; Lamb D; Kuo CW; Brighty DW
J Biol Chem; 2007 Dec; 282(50):36724-35. PubMed ID: 17940280
[TBL] [Abstract][Full Text] [Related]
8. Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.
Mirsaliotis A; Nurkiyanova K; Lamb D; Woof JM; Brighty DW
J Virol; 2007 Jun; 81(11):6019-31. PubMed ID: 17376912
[TBL] [Abstract][Full Text] [Related]
9. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
Shu W; Liu J; Ji H; Radigen L; Jiang S; Lu M
Biochemistry; 2000 Feb; 39(7):1634-42. PubMed ID: 10677212
[TBL] [Abstract][Full Text] [Related]
10. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.
Chu LH; Chan SH; Tsai SN; Wang Y; Cheng CH; Wong KB; Waye MM; Ngai SM
J Cell Biochem; 2008 Aug; 104(6):2335-47. PubMed ID: 18442051
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of the human respiratory syncytial virus fusion protein core.
Zhao X; Singh M; Malashkevich VN; Kim PS
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14172-7. PubMed ID: 11106388
[TBL] [Abstract][Full Text] [Related]
12. A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
Gaillard V; Galloux M; Garcin D; Eléouët JF; Le Goffic R; Larcher T; Rameix-Welti MA; Boukadiri A; Héritier J; Segura JM; Baechler E; Arrell M; Mottet-Osman G; Nyanguile O
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137809
[TBL] [Abstract][Full Text] [Related]
13. Leash in the groove mechanism of membrane fusion.
Park HE; Gruenke JA; White JM
Nat Struct Biol; 2003 Dec; 10(12):1048-53. PubMed ID: 14595397
[TBL] [Abstract][Full Text] [Related]
14. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
15. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Wild C; Oas T; McDanal C; Bolognesi D; Matthews T
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243
[TBL] [Abstract][Full Text] [Related]
16. Design and characterization of human respiratory syncytial virus entry inhibitors.
Ni L; Zhao L; Qian Y; Zhu J; Jin Z; Chen YW; Tien P; Gao GF
Antivir Ther; 2005; 10(7):833-40. PubMed ID: 16312179
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.
Sun Y; Zhang H; Shi J; Zhang Z; Gong R
Viruses; 2017 Sep; 9(9):. PubMed ID: 28906430
[TBL] [Abstract][Full Text] [Related]
18. Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides.
Mathieu C; Augusto MT; Niewiesk S; Horvat B; Palermo LM; Sanna G; Madeddu S; Huey D; Castanho MA; Porotto M; Santos NC; Moscona A
Sci Rep; 2017 Mar; 7():43610. PubMed ID: 28344321
[TBL] [Abstract][Full Text] [Related]
19. Peptide inhibitors of dengue virus and West Nile virus infectivity.
Hrobowski YM; Garry RF; Michael SF
Virol J; 2005 Jun; 2():49. PubMed ID: 15927084
[TBL] [Abstract][Full Text] [Related]
20. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection.
Wang C; Xia S; Wang X; Li Y; Wang H; Xiang R; Jiang Q; Lan Q; Liang R; Li Q; Huo S; Lu L; Wang Q; Yu F; Liu K; Jiang S
J Med Chem; 2022 Feb; 65(4):2809-2819. PubMed ID: 33929200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
